The big B. Quadria Capital, a Singapore-based healthcare-focused private equity firm, just announced the final close of its Fund III, with $1.07B in total commitments!

• The fund exceeded its initial target of $800M despite a challenging fundraising environment.
• Oh, and the fundraise is also around 60% larger than the firm’s previous $600M fund raised in 2020. 

LP check. Their existing backers include North American and European sovereign wealth funds, asset managers, and strategic corporates. 

• The Fund also got new commitments from institutional investors in Saudi Arabia, the UAE, and Bahrain. Major banks, insurance companies, and family offices from India also joined the round. 
• The Fund also received re-up commitments from impact investors. 

‍

💵 Where will the $$$ go? 

The Fund will invest in around 10 market-leading companies, taking both significant minority and majority stakes. 

• So far, the Fund is already nearly 40% deployed (including closed and signed investments). 
• The fund has invested in Aragen Life Sciences (a global contract research development and manufacturing organization), NephroPlus (an Asian dialysis chain), and Maxivision (an Indian eye care chain). 

Next steps. The Fund will make two new investments in SEA soon. Oh, and the firm is also opening a new office in Jakarta. 

‍

👀 About Quadria Capital

Founded in 2012, Quadria Capital manages over $4B in assets across 27 investments in Asia.